dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

More Industry Headlines

Improving surgical outcomes by imaging head and neck tumors in real time Researchers use tech developed by Perimeter Medical Imaging

Future-ready medical devices - Answering the current and future needs of patients and users

Mastering microbes in the healthcare setting Killing bacteria, chemical-free

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

Fivefold difference found in Medicaid reimbursements for radiotherapy May limit access to healthcare, especially in rural areas

First ultra high-res CT scan performed on US patient Scanner at UC Davis can image anatomy as small as 150 microns

Aidoc announces $27 million in VC funding to advance AI in imaging Brings company's total funding to $40 million

Innovations sparking quantum leap in remote cardiac monitoring technology A look at where we've been and where we're heading

Canon's Vital Images wins DoD contract Maximum $100 million fixed‐price contract for radiology and imaging systems

Joint Commission fluoro mandate may confuse providers, say experts Requires max exposure rates of imaging modes for fluroscopy devices

Dr. Colleen Lawton

ASTRO calls for proton beam therapy coverage

by Lauren Dubinsky , Senior Reporter
The American Society for Radiation Oncology (ASTRO) announced that it is now calling for private insurers and Medicare to provide coverage for proton beam therapy (PBT) in certain circumstances.

ASTRO outlines it in the new Model Policy it issued last week. The radiation oncologists and medical physicists who created it explain that they support PBT coverage for appropriate patients, and also identify the areas of that coverage where there is evidence that development and more research is needed.

Story Continues Below Advertisement

Free Marketplace where Lenders Compete Get Pre-Approved for up to $500,000

Get financing today. We say YES more! Easy, Fast, Application. Pick the payment that best works for you. Tax Benefits + Leasing = Huge Savings! NEVER BE OBSOLETE. NO DOWN PAYMENT. FIXED MONTHLY PAYMENT. MRI, CT, Ultrasound, Digital X-ray, Dental Equipment



"It is ASTRO's role to provide our expertise to payers [toward a result] that ensures access to PBT for the appropriate cancer patients," Dr. Colleen A.F. Lawton, chair of ASTRO's board of directors, told DOTmed News.

PBT is a controversial technology due to its cost and that there is not clear evidence that it is more efficacious or offers reduced side-effect when compared to other type of radiotherapy.

The reason why PBT costs significantly more than radiotherapy is because building a proton beam therapy facility comes with a price tag in the neighborhood of $100 million and up. But despite the cost, PBT has been shown to be effective for several pediatric cancers, particularly in the brain, and for some adult cancers, including ocular melanoma.

But research for breast, prostate and lung cancer is still ongoing, and clinical trials supported by the National Cancer Institute are currently gathering patients in all three disease sites at the 14-plus proton therapy treatment centers in the country.

ASTRO is recommending that PBT be covered for the areas in which it has been proven effective, as well as the areas that are still being studied. "We are calling for coverage for patients participating in clinical trials so that we will have the data needed to confirm PBT's effectiveness for other cancers," said Lawton.

But this is not the first time ASTRO has pushed for coverage for PBT. Last September, the society issued its Choosing Wisely list that outlines five things that physicians and patients should question, including not using PBT for prostate cancer unless it is part of a clinical trial.

The society is also calling for the coverage of PBT for patients who have cancers that are difficult to treat, or highly complex or rare cases where the therapy can provide advantages over other treatment options.

Lawton is "extremely hopeful" that insurers and Medicare will accept the Model Policy because ASTRO has developed it to meet existing evidenced-based care. She added that it's very critical that patients are able to participate in clinical trials so that there will be data to validate appropriate treatment.

Back to HCB News
  Pages: 1

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED